Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Nivolumab + AVD in Advanced Hodgkin Lymphoma
NCT06984146Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in classic Hodgkin lymphoma (cHL). Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06984146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06984146.